finance.yahoo.com ·
h c wainwright wells fargo 212102429
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAnalyst price target increases for MannKind (MNKD) reflect optimism on upcoming PDUFA decisions for Afrezza and Furoscix, and royalty/collaboration revenue streams. The impact is company-specific, with no direct commodity or supply-chain mechanism. Commercial mechanism is weak; the news is primarily equity analyst sentiment.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- H.C. Wainwright raised MNKD price target from $8 to $10 on May 7, maintaining Buy.
- Wells Fargo raised MNKD price target from $8 to $10, maintaining Overweight.
- First-quarter results fell short of expectations.
- Upcoming PDUFA decisions for Afrezza and Furoscix are potential catalysts.
- MannKind is involved with Ralinepag DPI.
Positive PDUFA outcomes for Afrezza or Furoscix could lead to flat movement in MNKD over the mid-term, with uncertainty around actual upside potential.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid